NeopharmCO.,LTD.
Financials
Valuation Metrics
NeopharmCO.,LTD.'s Market Cap is ₩3598B. At end of 2025 it was ₩2944B. Ranked #549 of 2,410 in KR market (top 23%), #217 of 1,631 on KOSDAQ (top 13%), #10 of 56 in Household & Personal Products (top 18%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 359.83B KRW | KR#549/2,410 Sec#10/56 |
| Revenue | 148.39B KRW | KR#1,191/2,410 Sec#26/56 |
| Net Income | 30.65B KRW | KR#558/2,410 Sec#14/56 |
| Total Assets | 217.81B KRW | KR#1,250/2,410 Sec#26/56 |
| Net Assets | 195.36B KRW | KR#958/2,410 Sec#19/56 |
| Employees | 171 | KR#1,211/2,410 Sec#27/56 |
| Value | ||
| P/E | 11.74x | KR#967/2,410 Sec#24/56 |
| P/B | 1.84x | KR#1,933/2,410 Sec#44/56 |
| PEG | 0.55x | KR#714/2,410 Sec#23/56 |
| P/S | 2.42x | KR#1,939/2,410 Sec#48/56 |
| EV/EBITDA | 10.29x | KR#672/2,410 Sec#15/56 |
| FCF Yield | 7.57% | KR#737/2,410 Sec#15/56 |
| Profitability | ||
| ROE | 15.69% | KR#291/2,410 Sec#12/56 |
| ROA | 14.07% | KR#134/2,410 Sec#5/56 |
| Op. Margin | 21.89% | KR#137/2,410 Sec#2/56 |
| Revenue Growth | 19.89% | KR#553/2,410 Sec#12/56 |
| Earnings Growth | 21.27% | KR#696/2,410 Sec#23/56 |
| Financial Health | ||
| Debt Ratio | 11.49% | KR#175/2,410 Sec#5/56 |
| Total Debt | 1.06B KRW | KR#1,944/2,410 Sec#46/56 |
| FCF | 27.23B KRW | KR#436/2,410 Sec#10/56 |
| Cash | 26.82B KRW | KR#1,070/2,410 Sec#22/56 |
| Net Debt/EBITDA | -0.79x | KR#421/2,410 Sec#10/56 |
| Dividend | ||
| Div. Yield | 3.35% | KR#610/2,410 Sec#14/56 |
| Div. Growth | 25.00% | KR#391/2,410 Sec#11/56 |
| Performance | ||
| 1Y Return | 31.13% | KR#262/2,410 Sec#6/56 |
| 1M Return | -2.81% | KR#678/2,410 Sec#13/56 |
| From 52W High | -13.65% | KR#93/2,410 Sec#1/56 |
| 1Y MDD | -28.85% | KR#203/2,410 Sec#4/56 |
| Trading | ||
| Volume | 19,279 shares | KR#1,184/2,410 Sec#31/56 |
| Trading Value | 431.5M KRW | KR#650/2,410 Sec#15/56 |
| Foreign Own. | 27.74% | KR#134/2,410 Sec#6/56 |
| Per Share | ||
| EPS | 1,912 KRW | KR#465/2,410 Sec#12/56 |
| BPS | 12,188 KRW | KR#846/2,410 Sec#18/56 |
Company Info
Established in 2000, the company is a KOSDAQ-listed cosmetics manufacturer. Its largest shareholder became It's Hanbul after the 2017 merger of Hanbul Cosmetics and It's Skin. The company owns cosmetic brands such as Atopalm, Real Barrier, Derma:B, Tl's, and Zeroid, with 83% domestic sales and 17% exports. Utilizing its proprietary MLE formulation technology, it develops products by understanding skin barrier function and expands its business through new formulation development. Neopharm is headquartered in Yuseong-gu, Daejeon.